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ABSTRACT
DOPAMINE AGONISTS MODIFY THE DEVELOPMENT
OF BRAIN D1 AND D2 RECEPTOR RESPONSIVENESS
by
Anwar Hamdi, M.D.
Dopamine (DA) agonist-induced behavioral
supersensitivity in the adult rat has served as the standard
model for certain of the motor and behavioral side effects
associated with long-term exposure to OA agonists in humans.
The mechanisms relating receptor events with behavior
mediation, however, remain unclear.
The striatum of rats progresses through a prolonged and
varied postnatal developmental period.
In order to examine
the relative contribution of D1 and D2 receptor-mediated
mechanisms to behavioral changes which follow chronic
dopamine agonist exposure, developing rats were treated
daily from birth with a D1 agonist, SKF 38393 hydrochloride
(3.0 mg/kg x 32d, i.p.), or a D2 agonist, LY 171555
hydrochloride (3.0 mg/kg x 32d, i.p.), and/or 6-OHDA (134
/<g, i.c.v., at 3 d after birth). Following a drug-free
interval, behavioral responses to selective DA agonists were
evaluated.
The results indicate that (1) prolonged LY 171555
treatments in development produced a supersensitive animal
model for yawning and eating behaviors.
(2) Perioral
movements of high frequency could be produced by a very low
dose of the DA D2 antagonist spiroperidol in rats treated
neonatally with 6-OHDA, thereby providing a useful animal
model to study tardive dyskinesia.
(3) The "priming"
phenomenon described by Breese and co-workers which was
thought to be produced by D1 agonists only has been found in
this study to be produced by a D2 agonist as well. This
model provides a means for studying specific stereotypic
behaviors in animals.
(4) [3HJSCH 23390 and
[3H]spiroperldol binding to striatal tissue was not altered
in rats treated 1n development with specific agonists or
antagonists for the D1 and D2 receptors. A neonatal 6-OHDA
lesion did not modify binding in any of the agonist- or
antagonist-treated groups.
In conclusion, DA D1 and D2 agonist treatments during
postnatal development are effective means of producing new
animal models that are potentially useful for studying
clinical disorders in man.
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CHAPTER 1
Introduction

Anatomical Review
Dopamine (DA), a catecholamine, is present as a
neurochemical in one of the most studied neurotransmitter
systems in the brain.

Until 1958, DA had been thought to be

only an intermediate precursor of norepinephrine and
epinephrine synthesis (Carlsson et al., 1958; 1959).
Largely on the basis of the fluorescence histochemical
procedure (Dahlstrom and Fuxe, 1964} and later
immunocytochemical procedure, DA-containing nerves were
mapped in the brain.

There are three major dopaminergic

neuronal systems in the brain (Lader, 1983).

These are as

follows:
1. One group of dopamine-neurons originates in the
ventral tegmental area and terminates in the
nucleus accumbens, olfactory tubercle, nucleus
interstitialis stria terminalis, hypothalamus,
preoptic area, cingulate cortex, hippocampus,
central amygdaloid nucleus, lateral septum,
prefrontal and entorhinal cortices, midbrain, and
ventromedial neostriatum.

This so-called A10

group is commonly known as the mesolimbocortical
DA system (Beckstead et al., 1979).
1

2. A more lateral group of DA cells, designated
the A9 or mesostriatal DA system, originates in
the substantia nigra pars compacts.

These neurons

project mainly to the neostriatum (caudate nucleus
and putamen), amygdala, nucleus accumbens, bed
nucleus of the stria terminalis, anteromedial
cortex, entorhinal area, globus pallidus, sub
thalamic nucleus, and cingulate cortex.
3. A system consisting of short neurons arising
mainly in the anterior part of the arcuate nucleus
and the ventral periventricular nucleus of the
hypothalamus (A12) terminates in the external
layer of the median eminence (the tuberoinfundibular DA system), pars intermedia, and
neural lobes of the pituitary (tuberohypophyseal
DA system), and infundibular stalk (Nauta et al.,
1978; Beckstead et al., 1979).

Other short

dopaminergic pathways are the incertohypothalamic,
which links the hypothalamus and lateral septum,
and the medullary periventricular nucleus in the
periaqueductal grey matter.

Proposed Functions Of Dopamine Systems
The physiology and pharmacology of DA from the
standpoint of its function as a neurotransmitter or
modulator in the central nervous system (CNS) has been

established, and it is accepted now that the dopaminergic
system is involved in:
1. Modulation of a variety of behaviors including:
ambulation or locomotion (Ungerstedt and
Arbuthnott, 1970; Pijnenburg et al.f 1976),
stereotyped behaviors (Creese and Iversen, 1973),
self-stimulation behavior (Phillips and Fibiger,
1973), stimulus control behavior (Ho and Huang,
1975), conditioned avoidance responding behavior,
feeding and drinking (for references see Kostrzewa
and Jacobowitz, 1974; Kostrzewa, 1989), rewardseeking behavior (German and Bowden, 1974; Wise,
1978), latent inhibition in which prior exposure
to a stimulus not followed by reinforcement
retards subsequent conditioning to that stimulus
(Weiner et al., 1984; 1987; Weiner and Feldon,
1987), as well as mechanisms controlling memory
consolidation and retention (Routtenberg and
Holzman, 1973; Major and White, 1978; Coulombe and
White, 1980; White, 1988).
2. Neuroendocrine function (tuberohypophyseal
dopaminergic system) including:

hypothalamic

secretion of releasing factors, gonadal secretion
of steroids, and pituitary secretion of prolactin.

Dopamine Receptors

It is now well established on the basis of biochemical,
anatomical, pharmacological, and behavioral characteristics
that brain DA can act on at least two distinct subtypes of
DA receptors (Kebabian, 1978; Kebabian and Caine, 1979;
Creese et al., 1983; Stoof and Kebabian, 1984; Onali et al.,
1985; Weiss et al., 1985).

The D1 type DA receptor is

coupled to an adenylate cyclase (AC) such that receptor
occupancy by an agonist increases cyclic adenosine 3*5'monophosphate (cAMP) formation (Hyttel, 1978).

The D2 type

DA receptor, on the other hand, is either unlinked or linked
to adenylate cyclase in a negative manner such that receptor
occupancy by an agonist decreases cAMP formation (Stoof and
Kebabian, 1981; Onali et al., 1984; Battaglia et al., 1985).
The existence of these two receptors has been supported
by the identification of agonists and antagonists selective
for either of these receptors.

Studies Directed Specifically to Dopamine D1 and D2
Receptors
The increasing availability of drugs which act
selectively on D1 or D2 DA receptors now permits a more
detailed evaluation of their response to chronic blockade or
stimulation.
The D2 DA receptors in the CNS have been labeled by
using the selective D2 antagonist, [3H]spiroperidol (Creese

et al., 1977a; Leysen et al., 1978; Laduron et al., 1978;
Creese, 1982).

These autoradiographic studies show high

densities of autoradiographic grains in the olfactory
tubercles, nucleus accumbens, nucleus caudate-putamen,
lateral septum, zona incerta, nucleus subthalamicus, arcuate
nucleus, central nucleus of the amygdala, claustrum,
prelateral and lateral mammillary nuclei of the
hypothalamus, nucleus of the lateral optic tract, dorsal
interpeduncular nucleus, ventral tegmentum, substantia
nigra, superior and inferior colliculi, parts of
periaqueductal grey, portions of the midline, cerebral
cortex (Klemm et al., 1979), hippocampus, pineal gland, and
the cerebellum (Bruinnk and Bischoff, 1986).

The most dense

aggregates are found in the striatum and nucleus accumbens
(Gehlert and Wamsley, 1984).
D1 DA receptors have been studied by using the nonselective radioligands cis-[3H]piflupentixol and cis-(Z)[3H]pifluthixol (Hyttel, 1978; 1981).

A newer selective

antagonist for D1 sites, SCH 23390, the 3-methyl 7-chloro
analog of SKF 38393, [{R)-(+)-8-chloro-2,3,4,5-tetrahydro-3methyl-5-phenyl-lH-3-benzazepine-7-51] (Iorio et al., 1983;
Hyttel, 1983), crosses the blood brain barrier and is
subject to extensive first-pass metabolism (the ID50 of SCH
23390 given orally is about 100-fold higher than after
intraperitoneal [i.p.] administration).

This novel

benzazepine exhibits nanomolar potency in inhibiting

dopamine stimulation of striatal adenylate cyclase activity
(Onali et al., 1984; Plantje et al., 1984; Hyttel, 1984) and
has a Ki value of approximately 0.5 nM for the striatal D1
DA receptors (Cross et al., 1983; Hyttel, 1983; Billard et
al., 1984; Schulz et al., 1984).

Treatment with SCH 23390

(0.50 mg/kg, s.c.) prior to peripheral administration of
EEDQ (the protein-modifying reagent N-ethoxycarbonyl-2ethoxy-1,2-dihydroquinoline) protects D1 DA receptors from
irreversible blockade by EEDQ, while neither D2 DA nor S2
serotonin receptors are protected (Hess and Creese, 1986).
Commercial [3H]SCH 23390 has a low level of nonspecific
binding, high specific activity (Billard et al., 1984;
Andersen et al., 1985), and specifically labels D1 sites
both in vitro and in vivo (Billard et al., 1984; Schulz et
al., 1984; 1985; Andersen et al., 1985; Andersen and
Nielsen, 1986).

Autoradiographic studies with [3H]SCH 23390

show that D1 DA receptors are present in abundance in the
corpus striatum, olfactory tubercle, nucleus accumbens,
dorsomedial prefrontal cortex, lateral preoptic area, globus
pallidus, amygdala, lateral septum, parietal cortex,
hippocampus, hypothalamus, olfactory bulb, cerebellum, and
brainstem (Schulz et al., 1985).

Very low numbers of D1

sites are observed in the ventral tegmental area (Dawson et
al., 1986).

Within the nigrostriatal system, D1 sites are

found only postsynaptically within the striatum (Pilloux et
al., 1987; 1988) and presynaptically in the substantia nigra
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(Altar and Hauser, 1987; Filloux et al., 1988).

Dopamine Receptor Distribution
The D1 and D2 DA receptors show different distribution
and number in the brain, have different neuronal
localization, and have different molecular size.

In

addition, their number changes with age, after long-term
neuroleptic treatment, and after 6-hydroxydopamine (6-OHDA)
lesions.

The affinity of both neuroleptics and agonists for

these receptors is very different.
Quantitatively, it has been hypothesized that there may
be about four times as many D1 DA receptors as there are D2
DA sites in the striatum (Leff et al., 1984) and olfactory
tubercles (Hyttel, 1978).

More D1 than D2 sites are also

found in the nucleus accumbens.

The ordered ratio of D1/D2

sites in the brain is striatum> nucleus accumbens> olfactory
tubercles.

Function and Interaction of DA D1 and D2 Receptors
The manner in which D1 and D2 DA receptors interact in
the brain to carry out their function is still unclear, even
though intensive studies have been directed toward
understanding the relative contributions of D1 and D2
receptor subtypes in mediating physiological and behavioral
phenomena.

Available evidence suggests that D2 systems are

linked to a particular mode of expression of behavior, such

as stereotypy. D1 receptors mediate a discontinuous, non
stereotyped activation of behavior characterized by episodes
of a prominent grooming response interpolated among episodes
of sniffing with some locomotion and rearing, repetitive
mouth opening and clonic jaw movements (Rosengarten et al.,
1983; 1986; Kolloy and Waddington, 1984; 1985; 1987; 1988;
Starr and Starr, 1986; Johansson et al., 1987; Murray and
Waddington, 1989).

D1 systems appear to have a greater role

in influencing the intensity (enabling) of expression of the
mode selected by D2 systems, with the full expression of
dopaminergic behavior requiring concurrent stimulation of
both receptor subtypes (Molloy et al., 1986; Mashurano and
Waddington, 1986; Braun and Chase, 1986; Waddington, 1986;
Arnt et al., 1987).
It is now accepted that D1 and D2 DA receptor-activated
neuronal systems are not functionally isolated, but interact
in their modulation of motor function:
1. Catalepsy induced by SCH 23390, a D1
antagonist, can be prevented by pretreatment with
selective D2 agonists (Meller et al., 1985).
2. Behavioral effects of the D1 DA receptor
agonist, SKF 38393, which include non-stereotyped
sniffing, rearing, and locomotor responses, are
partially reversed by the D2 DA receptor
antagonist, metoclopramide (Molloy and Waddington,
1985).

3. Even though they occurs in unlesioned rats,
behavioral responses to D2 agonists are not
antagonized by SCH 23390, and responses to D1
agonists are insensitive to D2 antagonists in
animals either lesioned with 6-OHDA or depleted of
DA by treatment with reserpine or a-methyl-ptyrosine (Arnt, 1985a; 1985b; Arnt and Hyttel,
1985; Herrera-Marschitz and Ungerstedt, 1985;
Breese and Mueller, 1985; Breese et al., 1985a,b).
4. D2 DA receptors are not independently
responsible for mediating effects of non-selective
DA agonists such as apomorphine.

Rather, a

synergistic interaction between D1 and D2 DA
receptor-regulated processes appears to be
essential for the expression of behavioral
phenomena typically associated with non-selective
DA agonists.

The same is true for increases in

tonic single unit activity in the globus pallidus,
evoked by systemic administration of these agents.
The behavioral or physiological effects induced by
selective D2 agonists apparently require the
presence of endogenous DA concurrently stimulating
the D1 receptors (Walters et al., 1987).
5. SKF 38393 stimulates the release of cAMP from
superfused striatal tissue slices, and this effect
is antagonized by LY 141865, a selective D2 DA

receptor agonist (Stoof and Kebabian, 1981).
6. Low doses of spiroperidol induce abnormal
perioral movements in rats, which can be
potentiated by SKF 38393 (Rosengarten et al.,
1983; 1986).
7. Yawning induced by selective stimulation of DA
D2 receptors is eliminated by the DA D1 receptor
antagonist SCH 23390 (Serra et al., 1987).
8. In the dorsal striatum, the stimulation of DA
D1 receptors facilitates the release of [3H]GABA,
while stimulation of DA D2 receptors inhibits
[3H]GABA release (Girault et al., 1986).
9. DA acting on D1 or on D2 receptors,
respectively, inhibits or facilitates the
veratridine-evoked release of cholecystokinin
(Meyer and Krauss, 1983).
10. DA acting on D1 or on D2 receptors,
respectively, increases or decreases the
neurotensin level in striatum (Merchant et al.,
1989).
11. DA acting on D1 or on D2 receptors,
respectively, decreases or increases the substance
F level in striatum (Sonsalla et al., 1984).
12. Electroencephalogram (EEG) synchronization and
sedation, classically associated with neuroleptic
treatment, does not depend upon the selective
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blockade of either DA D1 or D2 receptors, but
instead requires concurrent blockade of both
subtypes of receptors (Bo et al., 1988).
13. In vitro studies have shown that haloperidol,
at concentrations which appear to be selective for
DA D2 receptor blockade, increases the release of
[3H]acetylcholine (ACh) from superfused striatal
tissue slices (Starke et al., 1983), and SCH 23390
is capable of inhibiting [3H]ACh release.
Consideration of the functional interaction between D1
and D2 receptors (Breese and Mueller, 1985; Breese et al.r
1985a,b; Barone et al., 1986; Carlson et al., 1987) could
have important implications in disorders such as Parkinson's
disease and schizophrenia, where stimulation or blockade of
postsynaptic DA receptors confers symptomatic benefit, and
where the ratio of D1 to D2 receptor blockade may be an
important determinant of drug action on functions mediated
by these receptor subtypes.

6-OHDA and Dopamine Receptors
The specific catecholamine neurotoxin 6-OHDA produces a
selective permanent destruction of catecholamine cell bodies
and axon terminals in the brain (Ungerstedt, 1971; Uretsky
and Iversen, 1970; Kostrzewa and Jacobowitz, 1974).

In

adult rats, the destruction of DA nigrostriatal fibers is
associated with specific motor behavior dysfunctions; i.e.,

aphagia, adipsia, decreased body weight, akinesia (lower
level of spontaneous exploratory activity), lack of selfgrooming (Breese and Traylor, 1970; Evetts et al., 1970;
Creese and Iversen, 1973), increase in the striatal DA
receptors (Creese et al., 1977; Creese and Snyder, 1979;
Breese et al., 1984), and hypermotility and oral stereotypy
with a challenge dose of either D1 or D2 selective agonists
(Arnt, 1985b).
While 6-0HDA treatment of neonates produces a nearly
complete loss of brain catecholamines (Breese and Traylor,
1972), impairment in food intake is less than that seen in
an adult lesioned rat.
6-0HDA produces profound and permanent destructive
effects, especially on the DA efferents arising from A9.
This is evidenced by a near-complete loss of tyrosine
hydroxylase (TH), the rate-limiting enzyme in the DA
synthesis; a loss of TH-immunoreactive fibers in the
striatum and cell bodies in the substantia nigra pars
compacts; also a failure of intrastriatal horse radish
peroxidase (HRP) injections to label cells within the
substantia nigra.

A 2 to 3-fold increase in the amount of

striatal serotonin (5-HT) is detected at 2-5 months after
neonatal 6-0HDA treatment of rats (Stachowiak et al., 1984;
Breese et al., 1984).

This effect is accompanied by a

parallel increase in the uptake of [3H]5-HT into
synaptosomes prepared from striatum (Stachowiak et al.,

1984) and an enlargement of the serotonergic projections
from the raphe nucleus to the striatum, especially prominent
within the rostral striatum (Berger et al., 1985; Snyder et
al., 1986).

Since DA- and 5-HT-containing neurons have

similar effects on striatal interneurons (Davies and
Tongroach, 1978), it will become clear why neonatal 6-OHDA
treatment of rats could have some behavioral sparing.
Permanent supersensitive behavioral responses to
dopaminergic agonists, particularly the D1 receptor
agonists, occur in these rats when observed as adults.

The

Dl-induced behavioral responses include taffy pulling and
self-mutilatory behaviors.

Biochemically there is an

inability to up-regulate D1 and D2 receptors in response to
challenge doses of the respective antagonists in adults,
suggesting that neurochemical adaptation occurs after
neonatal 6-OHDA lesions, interfering with the capacity of
specific antagonists to increase the respective DA receptor
density (Duncan et al., 1987).

Neonatally lesioned rats are

subsensitive to the immobility effect typically produced by
both DA D1 and D2 antagonists in rats lesioned as adults
(Duncan et al., 1987).

Rats that receive 6-OHDA lesions as

adults do not show a progressive increase in response to
repeated administration of DA D1 agonist, SKF 38393, as do
the neonatally lesioned rats (Criswell et al., 1989).

Also,

there is no change in binding of [3H]SCH 23390 and
[3H]spiroperidol to rat striatum and nucleus accumbens in

14

adulthood (Breese et al., 1984; 1985a,b; 1986; Duncan et
al., 1987).
From the above it can be seen that the 6-OHDA lesions
of neonatal rats produce a model characterized by DA D1 and
D2 receptor supersensitivity in the absence of a change in
receptor number.

Disturbances Of The Dopamine Systems In Human CNS
Several serious disorders are known to be related to
disturbances in the function of the dopaminergic systems in
the brain.
Parkinson's disease is associated with a loss of the A9
DA system (Hornykiewicz, 1966).

Long term neuroleptic-

treatment is associated with extrapyramidal side effects,
including tardive dyskinesia (TD).

Huntington's chorea and

Gilles de la Tourette syndrome are characterized by
progressive chorea, cognitive impairment, and emotional
disturbance.

These latter disturbances have been attributed

to an increase in DA transmission (Butler et al., 1979;
Baldessarini and Tarsy, 1980; Spokes, 1980; 1981; Marsden,
1982).

The mesolimbocortical A10 DA system has been

implicated in the pathophysiology of schizophrenia.

Either

excessive release of DA or altered receptor sensitivity has
been implicated in the symptomatology of schizophrenia,
which is treated with dopaminergic drugs (Matthysse, 1973;
Stevens, 1973; Snyder, 1982; Chiodo and Bunney, 1983; White
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and Wang, 1983a,b}.
A complete understanding of the pathophysiologic role
played by DA in such conditions is not possible without a
knowledge of the development of the receptors which
represent transducers of the signals generated by this
neurotransmitter.

Antipsvchotics and Dopamine Receptors
Antipsychotics or neuroleptics are the drugs of choice
in the treatment of psychosis and other forms of
schizophrenia.

This class has also been used to treat the

dystonia symptoms of Huntington's chorea and Gilles de la
Tourette syndrome (Shapiro et al., 1978).
Using [3H]Haloperidol, an antipsychotic drug, and
[3H]DA, Seeman et al. (1975; 1976) have provided the first
direct evidence that neuroleptics compete with DA for
stereospecific DA binding sites.

The relative affinity for

D2 sites is directly proportional to clinical potency.
Considerable evidence indicates that long term
treatment with haloperidol results in the development of DA
receptor supersensitivity.

This is manifest as an enhanced

behavioral response to DA agonists (Gianutsos et al., 1974;
Bhargava and Ritzmann, 1980) and an increased number of
[3H]neuroleptic/dopamine receptor binding sites (upregulation) in the striatum (Burt et al., 1976; Muller and
Seeman, 1977; Matwyshyn and Bhargava, 1983; Mackenzie and
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Zigmond, 1985).

The major side effect, tardive dyskinesia,

which gradually develops in approximately 25% of
schizophrenics receiving chronic neuroleptics, is
characterized by uncontrollable purposeless and persistent
movements of the mouth, tongue, and extremities
(Baldessarini and Tarsy, 1980).

This resembles the

involuntary movements occurring in Parkinsonian patients
treated with L-DOPA, and can be reduced either by lowering
or raising the neuroleptic dose.

The proliferation of

neuroleptic/dopamine binding sites is observed after long
term administration of either butyrophenones or
phenothiazines (Clow et al., 1979; Wan et al,, 1983).

Ontogeny of Dopaminergic Neurons
There is a progressive increase in the striatal
concentration of DA and associated synthetic enzymes, such
as TH, DA-stimulated AC, which at birth, represent only 20%
of adult levels.

TH and AC attain adult levels by the age

of 3 to 4 weeks of postnatal life (Coyle and Axelrod, 1972;
Coyle and Compochiaro, 1976), and this has been attributed
to the proliferation and growth of axon terminals (Loizou
and Salt, 1970; Coyle and Axelrod, 1972).

Functional

dopaminergic-cholinergic interaction does not occur until
the second week of postnatal life (Coyle and Campiochiaro,
1976).

There is no spontaneous single unit activity of

striatal cells in eight-day-old rat pups.

At 17 days

striatal single unit activity is substantially less diverse
and of a lower frequency than that observed at 28 days.
Haloperidol induces single unit activity of striatal cells
at 28 days, but not at 17 days (Napier et al., 1985).
Haloperidol induces a cataleptic response in 21 days rats,
but not in a 14 days rats (Coyle et al., 1985).

The growth

of 5-HT axons into the striatum begins late in development
(Lidov and Molliver, 1982) in comparison to the 5-HT
innervation of other structures and DA innervation of the
striatum (Specht et al., 1981).

Marked stereotypy to

apomorphine only appears at 21 days of age.
the response is weak and variable.

Before that,

Islands of dopaminergic

innervation, present in the striatum on day 5, nearly
disappear by day 15 (Olson et al., 1972).

In contrast, the

DA receptors appear in a uniform pattern beneath the corpus
callosum.

This patch extends further into the striatum and

is not as elongated as the fluorescent subcallosal streak.
Receptors then diminish medially and there are no islands of
receptors to correspond to the fluorescence (Murrin, 1982).
Neuronal cell division in the striatum is mostly complete
after the first few postnatal days in the rat (Das and
Altman, 1970), and there is some evidence for neuronal cell
death in the first two postnatal weeks, based on estimates
of the total number of neurons present in the striatum
(Fentress et al., 1981).

At the first day after birth, the

rat striatum contains only 12 and 24% of the adult level of
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DA and DOPAC, respectively.

The striatal DA content

increases somewhat slowly thereafter, reaching adult levels
by postnatal day 60.

DA content remains constant through

adulthood and senescence.

In contrast, DOPAC levels develop

more rapidly than DA levels, attaining adult values by 20
days after birth, a time when DA is less than 50% of adult
level.

DOPAC content remains unchanged through senescence.

Basal AC activity increases 6-fold from birth to postnatal
day 45.

Concentration-response curves for DA-stimulated AC

activity indicate that 100 uM DA induces a maximal
stimulation of cAMP in rats of different ages.

The effect

of this concentration of DA increases 4-fold from birth to
postnatal day 14 when the maximal responsiveness to DA is
observed.

The effectiveness of DA on AC production rapidly

returns to adult levels thereafter.

Striatal DA content

reaches 50% of the adult value by postnatal day 35 (Giorgi
et al., 1987).

DA content of the brain rises significantly

between 0-7 days after birth, with the greatest rise per
unit time occuring between 7 and 18 days.
attained at about 50 days. The most rapid

Adult levels are
increase in TH

activity is between the 7th and 18th day.
The above findings indicate that DA-containing neurons
gradually develop their functions during fetal life and the
first 4-8 weeks of postnatal life.
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Ontogeny of Dopamine D1 Receptors
The density of DA D1 receptors in rat striatum is only
9% of the adult value at birth and increases very rapidly
thereafter, so that by postnatal day 35 a peak value is
attained (Giorgi et al., 1987).

The maturation of DA D1

receptors and DA-stimulated AC activity in the striatum (and
other brain areas) precedes that of the presynaptic
dopaminergic neuron markers (Spano et al., 1976; Hohn and
Wuttke, 1979; Lamberts and tfuttke, 1981; Giorgi et al.,
1987).

DA D1 receptors increase in density more rapidly

than DA D2 receptors in the first two weeks postnatally.
The ratio of D1 to D2 receptors increases from 1.7 at 2 days
of age to 3.3 at 14 days of age (Zeng et al., 1988).

Ontogeny of Dopamine D2 Receptor
In vivo and in vitro studies have shown that DA D2
receptors double in number between day 5 and day 15 after
birth, and then gradually increase to adult levels by day 30
(Pardo et al., 1977; Murrin, 1982; Murrin and Zeng, 1986).
Since DA plays an important trophic role in the development
of a normal number of striatal DA receptors (Rosengarten et
al., 1983a; Miller and Friedhoff, 1986), it has been
suggested that the development of DA D2 receptors, and the
responses that they mediate, are dependent upon the
maturation of their corresponding presynaptic nerve
terminals (Rosengarten and Friedhoff, 1979; Deskin et al.,

1981).

Some reports do not support this view (Creese and

Iversen, 1973; Pardo et al., 1977).

Striatal presynaptic

receptors, which are D2 receptors, may be just starting to
function around the first week of life and may not attain
full maturity until the second postnatal week (Shalaby et
al., 1981).

Impairment_Of^Popamine Receptor Ontogeny
Rosengarten and Friedhoff (1979) found that prenatal
administration of haloperidol results in a persistent
decrease in postnatal striatal DA D2 receptors (Rosengarten
et al., 1983b),

The critical period for this prenatal

neuroleptic effect is between gestational days 15 and IB
(Rosengarten et al., 1983a).

This treatment also affects

muscarinic cholinergic activity in the striatum (increase in
binding sites) (Miller and Friedhoff, 1986).

On the other

hand, giving haloperidol to nursing dams for the first 21
days after birth, results in a 40ft increase in the number of
striatal DA D2 receptors in the nursing littermates, two
weeks after the last dose (Rosengarten and Friedhoff, 1979).
Treatment of neonatal rats with penfluridol, on alternate
days during the first postnatal week, does not affect the
development of striatal DA D2 receptors, although there is a
supersensitive response of these rats to the DA receptor
agonist, apomorphine (Coyle et al., 1981).
Kostrzewa and Saleh (1989) have shown that
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administration of the DA D1 receptor antagonist, SCH 23390
(0.3 mg/kg i.p.), or the DA D2 receptor antagonist,
spiroperidol (1.0 mg/kg i.p.), to rats once a day for 32
successive days from birth results in a marked impairment of
the development of striatal D1 receptors at 12 weeks (74%
reduction in the specific binding) and marked impairment of
the development of striatal D2 receptors at 12 weeks (74%
reduction in the specific binding), respectively.
It can be conclude from the above results that the
fetal and early postnatal periods in rats may be vulnerable
stages in the functional maturation of the central
dopaminergic system.

Investigation of the development of

this system might assist in understanding its physiological
significance.

Dopaminergic System and Behavior
Animal behavioral assays are an important tool for
elucidating actions of drugs used in the treatment of CNS
disorders.

The behavioral assays have been used to define

the characteristic profiles of DA antagonists and DA
agonists, in the hope of screening new drugs for therapeutic
value.

The behavioral assays used most commonly are as

follows:
1. The rotational model, which usually includes
unilateral 6-OHDA lesions of the substantia nigra
or of the median forebrain bundle of rats.

A

contralateral circling response (away from the
lesioned side) is produced by DA agonists which
preferentially stimulate supersensitive DA
receptors on the denervated side.

Conversely, an

ipsilateral circling response is produced by
dopaminomimetics which release DA from intact
dopamine neurons on the non-lesioned side,
resulting in postsynaptic stimulation of DA
receptors on the intact side.
2. The stereotypy model, which includes
observation of such behaviors as licking, gnawing,
biting, chewing (oral stereotypy), sniffing,
rearing, grooming, and locomotion in rats.
3. The catalepsy model is best described as a loss
of locomotor behavior and an exaggeration of
bracing responses to stimuli.

This categorization

is operationally defined, for example, by placing
a rat's forepaws over a horizontal bar and
observing time of immobility in the imposed
posture.

Catalepsy results from blockade of DA D1

and/or D2 receptors in the striatum.

It is known

that these receptive site are restricted to
quinolinic acid-sensitive intrinsic neurons
(Calderon et al., 1988).
4. The yawning response, which is elicited in
experimental animals by DA agonists.

This effect

is antagonized by the centrally acting DA
antagonists.

The receptors involved in this

behavior have characteristics in common with the
DA D2 autoreceptor (Mogilnicka and Klimek, 1977;
Nickolson and Berendsen, 1980; Yamada and
Furukawa, 1980; Gower et al.r 1984; Stable and
Ungerstedt, 1984; Serra et at., 1983a,b; 1984;
Dourish and Hutson, 1985; Yamada et al., 1986;
Stoessl et al., 1987).

However, according to some

studies these receptors are located
postsynaptically (Serra et al., 1986).
Nevertheless, 6-OHDA lesions of DA neurons abolish
the yawning response (Dourish and Hutson, 1985;
Stoessl et al., 1987).
5. Perioral movements (abnormal mouth movements =
oral dyskinesia).

In humans, repetitious opening

and closing of the mouth and high frequency clonic
jaw movements are the most outstanding
characteristic of tardive dyskinesia which results
from prolonged neuroleptic treatment.

Perioral

movements in normal rats can be induced by
selective stimulation of the DA D1 receptors or by
selective blockade of D2 receptors with
antagonists (Molloy et al,, 1986; Rosengarten et
al., 1986; Koshikawa et al., 1987; Molloy and
Waddington, 1988).

Rats with reduced numbers of
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D2 receptors, resulting from strain difference,
senescence, or pharmacological intervention in
development demonstrate increased oral activity
after D1 agonist treatment (Rosengarten et al.,
1983c; 1986).

Oral behavior is increased in rats

treated chronically with several neuroleptics
(Clow et al., 1979; Waddington and Gamble, 1980;
Waddington et al., 1981).

The incidence of oral

activity is least when DA D2 as well as DA D1
receptors are stimulated (Rosengarten et al.,
1986; Johansson et al., 1987).

Heterogeneity of the Striatum
The striatal internal organization of afferent and
efferent projections is heterogeneous (Dray, 1979).

The

dorsal and ventral striatum are different in internal
organization, embryonic origin, efferent and afferent
projections (Joyce, 1983), and neurotransmitter content.
More DA is present in the dorsal part and more 5-HT and
norepinephrine are in the ventral part (Widmann and Sperk,
1986).
Dopaminergic drugs injected into different regions of
the striatum may interact with different elements of the
striatum and produce diverse behavioral effects (Costal et
al., 1980; Joyce et al., 1981).

The dorsal rostral region

supports the rearing response; a more caudal and medio-
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ventral region is involved in biting; and a rostro-ventral
region sustains the hyperactivity response (Joyce, 1983).
These findings emphasize the functional (behavioral)
heterogeneity of the striatum (Dunnett et al., 1981a,b).
After intraventricular 6-OHDA treatment, extensive loss of
DA terminals occurs in medial portions of the striatum,
while large numbers of terminals remain intact in more
lateral areas (Onn et al., 1986).

Rationale
One factor that influences the clinical manifestation
of any lesion in the CNS is the age of the brain at the time
of the lesion.

Although a lesion is static, its effect(s)

on neurologic function is affected as the system matures.
Since the striatum progresses through a prolonged and varied
postnatal developmental period, DA receptor stimulation or
blockade and/or dopaminergic fiber distruction during this
interval is likely to alter development of receptor sites.
The change may be quite different from that which is
observed after a similar lesion in the adult.
Several drugs and neurotoxins administered to
developing rats produce different biological consequences
from those observed in adults.

Chronic treatment of mature

animals with neuroleptics leads to DA D2 receptor
proliferation (Neve et al., 1985).

Once the neuroleptic is

withdrawn, the numbers of D2 receptors return to control

levels in a matter of days.

However, when the dopaminergic

system is altered during early development with prenatal
treatment with DA D2 antagonists (Rosengarten and Friedhoff,
1979), or postnatal treatment with DA D1 or D2 specific
antagonists (Kostrzewa and Saleh, 1989), DA receptor downregulation is observed.

The changes in the system are

permanent, persisting through adulthood.
Breese et al. (1984) demonstrated that the behavioral
responses to DA agonists are distinctly different in
neonatal and adult 6-OHDA-lesioned rats.

Other differences

between adult and neonatal 6-OHDA-lesioned rats have also
been described.

Rats treated with the neurotoxin as adults

exhibit a profound aphagia, adipsia, and akinesia (Zigmond
and Strieker, 1973).

In contrast, after neonatal 6-OHDA

treatment, rats do not display such an acute behavioral
syndrome (Duncan et al., 1987).

Also, neonatal destruction

of brain dopaminergic neurons with 6-OHDA results in a
selective supersensitivity of D1 receptors in the absence of
an altered number of receptors (Breese et al., 1984,
1985a,b, 1986).

Whereas neonatal 6-OHDA-lesioned rats show

a greater response to D1 receptor agonists than to D2
receptor agonists, adult 6-OHDA-lesioned rats show a greater
sensitivity to D2 receptor agonists than to D1 agonists
(Breese et al., 1985b).

Chronic treatment with the specific

DA D1 antagonist, SCH 23390, or DA D2 antagonist,
haloperidol, produces a significant elevation in [3H]SCH
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23390 or [3H]spiroperidol binding, respectively, in
unlesioned and in 6-OHDA adult-lesioned rats.

The same

chronic treatment in adult animals that were lesioned as
neonates with 6-OHDA did not result in an up-regulation of
the respective receptors (Duncan et al,, 1987).
Several measures of dopaminergic function in striatum
and other brain areas are reduced in patients with LeschNyhan syndrome, a disease associated with an inborn
deficiency of the enzyme hypoxanthine-guanine phosphoribosyl
transferase.

Parkinson's disease is another syndrome in

which brain dopamine is reduced.

However, Parkinson's

patients display tremor, bradykinesia, stiffness, and do not
demonstrate the choreoathetoid movements, hypertonicity, the
unique compulsive self-mutilation behavior (SMB) of digits
and tissue about the mouth, or the elevation in serotonin in
the striatum observed in children with Lesch-Nyhan disease.
Apparent differences in these syndromes are the age of onset
of the symptoms (the age at which dopaminergic pathways are
destroyed) and the disordered purine metabolism in LeschNyhan patients.
The adult 6-OHDA-treated rats has been used as a
neurochemical model of Parkinson's disease.

Breese et al.

(1984; 1984a) have suggested that the neonatal 6-OHDAtreated rat may serve as a model of central dysfunctions
observed in childhood diseases with reduced brain dopamine.
Lesch-Nyhan syndrome is one of those diseases.

Dopamine D2 agonists are useful in Parkinsonism and do
not appear to initiate self-mutilation behavior in rats
treated neonatally with 6-OHDA (Breese et al., 1985a).

It

is not known whether administration of the D2 agonist would
be beneficial to the motor dysfunction in the Lesch-Nyhan
syndrome, or would exacerbate the choreic symptoms as
observed with L-dopa in Huntington's chorea (Breese et al.,
1985a).

One goal of the present experiment was to shed

light on this important clinical question.
Agonist-induced behavioral supersensitivity has served
as the standard animal model for certain of the motor and
behavioral side effects associated with long-term exposure
to DA agonists in humans.

Its pharmacologic mechanism,

however, remains unclear (Braun and Chase, 1988).

In order

to examine the relative contribution of D1 and D2 receptormediated mechanisms to the behavioral changes which follow
chronic dopamine agonist exposure, either the R-enantiomer
of SKF 38393 {2,3,4,5-tetrahydro-7,8-dihydroxy-l-phenyl-lH3-benzazepine), the most selective, partial D1 agonist,
(Pendleton et al., 1978; Setler et al., 1978; Watling and
Dowling, 1981; Sibley et al., 1982) or the selective, full
D2 agoniBt, LY 171555, (trans-4-4a,5,6,7,8,8a,9-octahydro-5propyl-lH-pyrazolo(3,4-g) quinoline.), the (-)isomer of LY
141865 (Tsuruta et al., 1981; Gundlach et al., 1983; Stoof
and Kebabian, 1984; Plantje1 et al., 1985} was administered
alone or in combination with 6-OHDA to rats during the
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postnatal period.

Following a drug-free interval,

behavioral responses to the selective DA agonists were
evaluated.
This study was undertaken with the objective of (1)
assessing both striatal DA D1 and D2 receptors in rats after
postnatal treatment with selective D1 or D2 agonists and
antagonists alone and in combination with neonatal 6-OHDA
treatment.

Other aims were to determine whether the above

treatments would (2) modify the ontogeny of the respective
receptor populations in the striatum, (3) modulate the
abnormal responses that occur following neonatal treatment
with 6-OHDA, or (4) alter the behavioral response(s) to
challenge doses of agonists or antagonists given in
adulthood.
A comprehensive study of the dopaminergic system is
needed in order to combine and compare the effects generated
by 6-OHDA and the effects generated by specific agonists and
antagonists on this system.
This study should lead to a better understanding of the
dopaminergic system and better enable an animal model to be
developed that can assist in the development of agents that
can be useful in the treatment for DA receptor
supersensitivity or subsensitivity caused by structural
damage or functional alterations in the brain.

CHAPTER 2
Materials and Methods

This project was divided into two parts.

The first

series of experiments were conducted to determine the effect
of chronic stimulation with specific agonists on the
ontogeny of DA D1 and D2 receptors.

The second series of

experiments were undertaken to test the ability of specific
postnatal treatment with D1 or D2 agonists or antagonists to
modulate the changes produced by neonatal 6-OHDA treatment.

An ima1s a n d ^Treatment
Timed pregnant Sprague-Dawley albino rats were obtained
from Charles River Labs (Research Triangle Park, NC) about 1
week before parturition, housed singly in plastic cages with
food and water ad libitum, and were kept on a twelve hour
light-dark cycle (on at 07:00 h) at 22+1 °C.

Date of litter

delivery was noted within 12 hours and the day of birth was
considered day 0.

At birth the pups from all litters were

randomly assigned to the mothers, and litters were culled to
a maximum of ten pups.

All offspring used in the study were

weighed once a day from birth until the end of treatment (32
days of age).
Starting at birth, all neonates were treated once a day
for 32 successive days by intraperitoneal (i.p.) injection
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with one of the following regimens: (a) saline (0,85ft) plus
saline containing tartaric acid (0.5%) and acetic acid (1.0
mM), (b) SCH 23390 HC1 (0.3 mg/kg, free base; Research
Biochemicals, Inc., Natick, MA) in saline (0.85ft) plus
saline-tartaric acid/acetic acid, (c) spiroperidol (0.3
mg/kg, Research Biochemicals) in saline-tartaric acid/acetic
acid plus

saline, (d) SKP 38393 HC1 (3.0 mg/kg, Research

Biochemicals), or

(e) LY 171555 HC1 (3.0 mg/kg, Lilly,

Research Labs, Indianapolis, IN). At 3 days after birth,
groups of rats receiving the above treatment were treated
with 6-OHDA hydrobromide (67.5 A ? intracerebroventricular,
i.c.v., free base, in each side; Regis Chemical Co.,
Chicago, IL) or the diluent, saline (0.85ft) with ascorbic
acid (0.1ft) to prevent the spontaneous oxidation of 6-OHDA.
Rats wereweaned at 4
rats from

weeks of age. At 38-41 days of age,

all theabove groups were challenged with the

specific DA D2 agonist, LY 171555, to study yawning
behavior.

At 44-47 or 49-51 days of age, rats were

challenged with the DA D1 specific agonist, SKP 38393 (3.0
mg/kg) or the DA D2 specific agonist, LY 171555 (3.0 mg/kg),
respectively, to study stereotypic behaviors.

At 70 days of

age, rats were challenged with the DA D2 specific
antagonist, spiroperidol (40 Ag/kg, i.p.), to study the oral
dyskinesia.
For the binding studies, a separate group of rats
untreated after 32 days was used.

These rats were killed by
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decapitation at 55 to 57 days.

Brains were immediately

removed and the striata were dissected free, frozen on dry
ice, and stored at -60 °C.
One rat treated with 6-OHDA did have post-decapitation
convulsions and was not used for assessment of D1 or D2
receptor number.

Tissue Preparation
At the time of assay, parts of striata from the same
medio-lateral and/or dorso-ventral location were placed in
100 volumes of 50 mM Tris buffer (pH 7.4) containing 120 mM
NaCl and 5 mM KC1.

After homogenization (setting of 50, 20

s; Tekmar Tissumizer), samples were centrifuged at 48,000 x
g for 25 min at 4 °C in a Beckman L5-75B ultracentrifuge.
This step was repeated after resuspending the pellets in 100
volumes of fresh buffer.

The final pellets were resuspended

in the Tris-salt solution.

D1 Binding Assay
To assess DA D1 receptor binding, the method of Schulz
et al. (1985) was employed.

Briefly, samples of 0.2 ml of

homogenate were added to 0.1 ml [3H]SCH 23390 (50 to 1500
pM, final conc.; Amersham, Monton Grave, IL) in Tris-salt
solution containing 2 mM CaC12. Samples (1 ml incubation
mix) were incubated for 15 min at 37 °C in a shaking water
bath and then rapidly filtered under partial vacuum on
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Whatman GF/F glass fiber filters using a Millipore
filtration unit.

Filters were washed three times with 5 ml

of ice-cold Tris-salt solution.

After drying, filters were

placed in 9 ml of Scintiverse £ (Fisher Scientific, Atlanta,
GA), and tritium activity was determined in a Beckman LS
9800 liquid scintillation spectrometer,

specific binding of

[3H]SCH 23390 was defined as the difference in binding in
the presence and absence of SCH 23390 (1/tM).

D2 Binding Assay
To assess DA D2 receptor binding, the method of Creese
and Snyder (1979) was used.

Aliquots of homogenate (0,2 ml)

were incubated with 0.1 ml [3H]spiroperidol (50 to 1500 pH,
final conc.; Amersham) in Tris-salt solution containing 0.5
mM MgC12.

Samples (1 ml incubation mix) were incubated for

15 min at 37 °C in a shaking water bath and then rapidly
filtered under partial vacuum on Whatman GF/F glass fiber
filters using a Millipore filtration unit.

Filters were

washed three times with 5 ml of ice-cold Tris-salt solution.
After drying, filters were placed in 9 ml of Scintiverse E
(Fisher Scientific), and tritium activity was determined.
Specific binding of [3H]spiroperidol was defined as the
difference in binding in the presence and absence of dbutaclamol (1/(M; Research Biochemicals, Inc.).
Since [3H]spiroperidol has been shown to bind to
serotonin-2 receptors (S2) (Leysen et al., 1978; Pertoutka
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and Snyder, 1979; Witby et al., 1980; Witby et al., 1981},
ketanserin was added to block serotonin receptors (Murrin
and Kuhar, 1979).

Ketanserin, at a concentration of 27 nM,

selectively binds to S2 sites allowing specific study of the
D2 receptors (Leysen et al., 1981; 1982; Hamblin et al.,
1984)..

Equilibrium Binding Studies
In order to determine the maximal binding capacity
(Bmax) and the apparent dissociation constant (Kd) for
[3H]SCH 23390 and [3H]spiroperidol receptor binding, a
double rectangular hyperbola model was used.

This describes

the interaction of a selective radioligand with two classes
of non-interacting binding sites {B = (Bmaxl)(L)/(L+Kdl) +
(Bmax2)(L )/{L+Kd2} + EL}, where B is the amount of
radioligand bound, Bmaxl and Bmax2 are the densities of the
two classes of binding sites, L is the free concentration of
radioligand, Kdl and Kd2 are the dissociation constants of
the binding sites for the radioligand, and E is the ratio of
non-specific binding siteB at the L concentration.

Since

the data could be fit by a single site model and since there
was no significant improvement in fitting provided by a two
site model, the Bmax2 was considered to be zero.
For [3H]SCH 23390 kinetic studies in rat striata, the
[3H]SCH 23390 concentrations ranged from 50 to 1500 pM (8
concentrations, total}.
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For [3H]spiroperidol kinetic studies in rat striata,
the [3H]spiroperidol concentrations ranged from 50 to 1500
pH (8 concentrations, total).

Behavioral Methods
In all behavioral studies rats were placed in separate
cages and were allowed to accommodate to the behavioral
testing laboratory for one hour prior to drug treatments.
To avoid possible circadian effects, behavioral observations
were conducted at the same time each day for the different
tests.
1. Yawning. Yawning was studied by administering a
challenge dose of the DA D2 specific agonist, LY
171555 (50 /lg/kg, i.p.; Serra et al., 1987).

Rats

were then placed in small Perspex observation
cages (48 x 26 x 18 cm) and observed individually.
Starting 5 min after LY 171555 injection, the
following behavior elements were scored over the
next 25 min: a) number of yawns, b) number of
penile erections, and c) duration of genital
grooming.

These sessions were carried out between

09:00 and 14:00 hr. in a quiet, well-lighted room.
2. Oral Dyskinesia. Oral dyskinesia (spontaneous
chewing jaw movements) were assessed by
administering a challenge dose of the specific DA
D2 antagonist, spiroperidol (40 Ag/kg, i.p.)

(Laduron et al., 1978; Leysen et al., 1978).

One

hour after spiroperidol treatment, the numbers of
oral movements were recorded for 1 min every 10
min for 6 periods (Rosengarten et al., 1983;
1986).

Chewing was recorded only if it appeared

to be purposeless, that is, if it was not directed
at any specific object.
3. Stereotypic Behavior. Behavioral observations
were made as has been described by Breese et al.
(1984; 1985a,b).

Following a 60 min adaptation

period in clear Perspex cages (48 x 26 x 18 cm)
with wood chip bedding on the floor, drugs were
administered.

Behavioral assessment was made for

a 1 min period once every 10 min for 90 min.

Each

min was divided into four 15 s periods and
behaviors were scored as occurring or not
occurring during each 15 s period.

Therefore, the

maximum score for any observed behavior in a 1 min
period was 4 (i.e., once in each 15 sec interval).
The behaviors observed were locomotion, rearing
(both front legs off the floor of the cage),
licking, sniffing (intense 8-10/sec directed
towards the sides or floor of the observation
cage), taffy pulling (coordinated movement of
front paws toward the mouth and then away from the
body), head nodding (head moving up-and-down or
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side-to-side in a repetitive fashion), paw
treading, jumping, digging, eating wood chips,
grooming, and self-biting.

Data Analysis

Binding studies
The means of Bmax and Kd values in different groups
were analyzed by the analysis of variance (ANOVA) followed
by a post-ANOVA Newman-Keuls test, in order to test for
significant differences between the treatment groups.

A p

value of <0.05 was considered to be the level for
statistical significance.

Yawning and Oral Dyskinesia
The results were expressed as the mean number of
responses per group ± S.E.M. to give an indication of
variability.

The statistical significance of the results

was evaluated by the analysis of variance (ANOVA) followed
by a post-ANOVA Newman-Keuls test,

A p value of <0.05 was

considered to be the level for statistical significance.

Stereotypic Behavior
Data are expressed as the mean total stereotypy score
for 90 min + S.E.M to give an indication of variability.
The statistical significance of the results was evaluated by

the analysis of variance (ANOVA) followed by a post-ANOVA
Newman-Keuls test.

A

e

value of <0.05 was considered to be

the level for statistical significance.

CHAPTER 3
Results

Enhanced Yawning Response to the DA P2 Specific Agonist
LY 171555 in Rats Treated During Development with
LY 171555
Rats treated daily during postnatal development with
the D2 receptor agonist LY 171555 (3,0 mg/kg/d, i.p.)
demonstrated an 89% increase in the number of yawns that
were induced by a challenge dose of LY 171555 (50/fg/kg,
i.p.).

In rats that were tested at 38 to 41 days after

birth, the incidence of LY 171555-induced yawning was 25.0 +
3.9 during the 25 minute observation period vs. 1 3 . 2 + 2 . 9
for that of the control group (p < 0.05, Figure 1 and Table
1).

The yawning response rate for rats treated in

development with spiroperidol (0.3 mg/kg/d, i.p.) was not
different from control.

When rats were treated neonatally

with 6-OHDA (200 /(g, salt form, i.c.v.), the enhanced
response of the LY 171555-treated group was eliminated.

The

yawning response to a challenge dose of LY 171555 was
approximately 3 yawns during the observation period for both
the diluent and LY 171555 groups.

However, neonatal 6-OHDA

treatment did not alter the number of yawns in the rats
treated with spiroperidol in development (Table 1, Fig. 1).
Treatment during development with SKF 38393 (3.0 mg/kg/d,
39
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i.p.) or SCH 23390 (0.3 mg/kg/d, i.p.) did not alter the
yawning response to the challenge dose of LY 171555 when
compared to the control.
The number of penile erections and the duration of
genital grooming were not statistically different between
the groups.

Enhanced Perioral Response to the DA D2 Specific Antagonist
Spiroperidol in Neonatal 6-OHDA-Lesioned Rats
Rats treated at 3 days after birth with 6-OHDA (200
Jig/kg, salt form, i.c.v.) demonstrated a 710% (7-fold)

increase in the number of clonic jaw movements that were
induced by a challenge dose of spiroperidol (40/fg/kg,
i.p.}.

In rats tested at 70 days after birth, the incidence

of spiroperidol-induced perioral movements (oral dyskinesia)
was 45.4 ± 9.9 during the observation period (1 min every 10
min for 6 times) vs. 5.6 + 2.0 for that of the control group
(p < 0.05, Table 2, Figure 2).

The clonic jaw response rate

for rats treated in development with SCH 23390 (0.3 mg/kg/d,
i.p.) or SHF 38393 (3.0 mg/kg/d, i.p.) alone was not
different from control, but when combined with 6-OHDA, the
enhanced response of the 6-OHDA-treated group was
eliminated.
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Table 1
Effects of Acute LY 171555 (50 Xfe/kg, i.p.) on Yawning in Rats
Treated During Development with Dopamine Agonists or Antagonists
Developmental
Treatment

No. Of Yawns

No. Of Penile
Erections

Duration Of Genital
Grooming (sec)

VEHICLE +
DILUENT

13.2 + 2.9

1.4 ± 0.8

7.4 ± 4.8

LY171555

25.0 + 3.9*'l'e

2.2 ± 1.2

12.3 + 5.0

SPIPERONE

12.6 + 2.6

2.8 + 0.5

19.4 + 4.6

SCH23390

9.0 + 2.0

1.0 ± 0.4

8.3 + 3.4

SKF38393

12.6 ± 1.2

2.0 + 0.5

14.2 + 5.2

DILUENT

3.0 + 0.3

1.2 + 0.2

9.4 + 6.2

LY171555

3.3 + 1.0

0.8 + 0.8

5.0 + 4.1

14.8 + 3.1b

1.3 + 0.3

12.3 + 2.5

SCH23390

7.2 + 2.1

1.6 ± 0.8

15.6 + 8.2

SKF38393

1.3 + 0.3

0.3 + 0.3

3.3 + 3.3

6-OHDA *

SPIPERONE

Rats were treated i.p., daily from the day of birth to 32
days after birth, with diluent, LY 171555 (3.0 mg/kg/d),
spiroperidol (spiperone) (0.3 mg/kg/d), SCH 23390 (0.3
mg/kg/d) or SKF 38393 (3.0 mg/kg/d). All rats were also
treated i.c.v. at 3 days after birth with 6-OHDA (200 Mg,
salt form) or diluent. At 38 to 41 d after birth, rats were
challenged with LY 171555 (50 Mg/kg, i.p.), and the numbers
of yawns and penile erections, and the duration of genital
grooming were recorded for 25 min, beginning 5 min after
acute LY 171555 treatment.
Each value representsthe Mean ± S.E.M. for 5 rats.
a,
e <
0.05,comparedto the 'Vehicle + Diluent1 group.
b,
p<
0.05,comparedto the '6-OHDA + Diluent' group.
c,
e <
0.05,comparedtothe 'LY 171555 + 6-OHDA' group.
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Figure 1. Effects of Acute LY 171555 (50/fg/kg, i.p.) on
Yawning in Rats Treated During Development with Dopamine
Agonists or Antagonists. Rats were treated i.p., daily from
the day of birth to 32 days after birth, with diluent, LY
171555 (3.0 mg/kg/d) or spiroperidol (0.3 mg/kg/d). All rats
were also treated i.c.v. at 3 days after birth with 6-OHDA
(200 /(g, salt form) or diluent. At 38 to 41 d after birth,
rats were challenged with LY 171555 (50/fg/kg, i.p.), and
the numbers of yawns was recorded for 25 min, beginning 5
min after acute LY 171555 treatment.
Each value representsthe Mean ± S.E.M. for 5 rats.
a, p <0,05, compared to the 'Vehicle + Diluent* group.
b, jj <0.05, compared to the '6-OHDA + Diluent* group.
c, p <0.05, compared to the 'LY 171555 + 6-OHDA* group.
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Table 2
Effects of Acute Spiroperidol (40 Jtg/kgt i.p.) on the Incidence
of Perioral Movements in Neonatal 6-OHDA-Lesioned Rats
Developmental
Treatment

No. Of Repetitive Jaw Movements

VEHICLE +
DILUENT

5.6 ± 2.0

SCH23390

4.8 + 3.1

SKF38393

3.4 ± 0.9

6-OHDA +
DILUENT

45.4 ± 9.9*

SCH23390

14.0 + 3.9*

SKF38393

3.0 + 1.7*

Rats were treated i.p., daily for the first 32 days from
birth, with diluent, SCH 23390 (0.3 mg/kg/d), or SKF 38393
(3.0 mg/kg/d), in combination with i.c.v. 6-OHDA (200>«g,
salt form) or its diluent at 3 days of age. Animals were
challenged with spiroperidol (40 /fg/kg, i.p.) at 70 days
from birth, and were observed one hour after the challenge
dose. Numbers of episodes of mouth movements (consisting of
bursts of repetitive jaw movements) were summed over 6 one
min periods, separated by 10 min intervals.
Results are expressed as the Mean + S.E.M. for 5 rats.
a, e < 0.05, comparedto the 'Vehicle + Diluent' group.
b, e < 0,05, compared to the '6-OHDA
+ Diluent1 group.
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Figure 2. Effects of Acute Spiroperidol (40/fg/kg, i.p.) on
the Incidence of Perioral Movements in Neonatal 6-OHDALesioned Rats. Rats were treated i.p., daily for the first
32 days from birth, with diluent or SKF 38393 (3.0 mg/kg/d),
in combination with i.c.v. 6-OHDA (200/lg, salt form), or
its diluent at 3 days of age. Animals were challenged with
spiroperidol (40><fg/kg, i.p.) at 70 days from birth or SKF
38393 (3.0 mg/kg, i.p.) at 77 days from birth, and were
observed one hour after the challenge dose. Numbers of
episodes of mouth movements (consisting of bursts of
repetitive jaw movements) were summed over 6 one min
periods, separated by 10 min intervals.
Results are expressed as the Mean ± S.E.M. for 5 rats.
a, jp < 0.05, compared to the 'Vehicle + Diluent* group.
b, p < 0.05, compared to the '6-OHDA
+ Diluent' group.

45

Enhanced Stereotypic Response to the DA D1 Specific Agonist
SKF 38393 in Rats Treated Purina Development.with
both SKF 38393 and 6-OHDA
Daily treatment of rats during postnatal development
with the D1 receptor agonist SKF 38393 (3.0 mg/kg/d, i.p.)
was not associated with remarkable changes in stereotypic
responses to a challenge dose of SKF 38393 (3.0 mg/kg, i.p.)
(Tables 3-6).

The neonatal 6-OHDA-lesioned rats (200 Mg,

salt form, i.c.v.) also showed no remarkable changes in
stereotypic responses to a challenge dose of SKF 38393
(Tables 3-6).

In rats treated in development with both 6-

OHDA and SKF 38393, there were marked changes in stereotypic
responses to the challenge dose of SKF 38393 at 44 to 47
days.

In this latter group there was a marked statistically

significant increase over control in the score for licking
(24.0 + 3 . 2 vs. 5,2 +2.1), grooming (15.6 + 4.4 vs. 3.4 ±
1.6), locomotion (26.8+ 3.5 vs. 7.6 + 2.7), jumping (8.0 +
4.6 vs. 0.0), taffy pulling (16.8 + 3.1 vs. 1.4 + 0.9), and
paw treading (14.0 ± 3.3 vs. 2.2 + 1.3) (Tables 3-6 and
Figures 3-8).
In the same group (SKF 38393 + 6-OHDA), the incidence
of SKF 38393-induced sniffing, digging, gnawing, eating,
rearing, head nodding, and self-biting was not different
from that of the control group (Tables 3-6).

A challenge

dose of SKF 38393 at 44 to 47 days did not modify the above
behaviors in rats treated in development with LY 171555 (3,0
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mg/kg/d), spiroperidol (0.3 mg/kg/d), or SCH 23390 (0.3
mg/kg/d).

Neonatal 6-OHDA (200 Mg, salt form, i.c.v., at 3

days of age) did not modify the responses to SKF 38393
challenge in these groups (Tables 3-6).

Stereotypic Responses to the DA D2 Specific Agonist
LY 171555 in Rats Treated During Development
with both SKF 38393 and 6-OHDA
Daily treatment of rats with SKF 38393 (3.0 mg/kg/d,
i.p.) during the postnatal development period was not
associated with remarkable changes in stereotypic responses
to a challenge dose of LY 171555 (3,0 mg/kg, i.p.) at 49 to
51 days of age (Tables 7-10),

The neonatal 6-OHDA-lesioned

rats (200 M<3, salt form, i.c.v.) also showed no remarkable
changes in stereotypic responses to a challenge dose of LY
171555 (3.0 mg/kg, i.p.) (Tables 7-10),

However, in rats

treated in development with both 6-OHDA and SKF 38393, there
were marked changes in stereotypic responses to a challenge
dose of the DA D2 specific agonist, LY 171555 (3.0 mg/kg,
i.p.).

The challenge dose of LY 171555 produced a marked

increase over control, in the score for licking (20.6 + 6.5
v s, 0.2 + 0,2), grooming (20.0 ± 6.9 vs. 0.0), and digging
(20.0 + 3.2 vs. 0.4 ± 0.2) (Tables 7,8 and Figures 3,4,9).
On the other hand, the challenge dose of LY 171555 reduced
the score for gnawing (4.4 ± 1.5 vs. 23.6 + 1.3) in this
same group (SKF 38393 + 6-OHDA) (Table 8 and Figure 10).

In

the same group (SKF 38393 + 6-OHDA), the incidence of LY
171555-induced sniffing, eating, locomotion, rearing,
jumping, taffy pulling, paw treading, head nodding, and
self-biting were not different from that of the control
group (Tables 7-10).

In rats treated i.p. from the day of

birth to 32 days of age with spiroperidol (0.3 mg/kg/d) or
SCH 23390 (0.3 mg/kg/d) and were challenged with LY 171555
(3.0 mg/kg, i.p.), there was no change in the incidence of
stereotypic behaviors at age 49 to 51 days.

Also, 6-OHDA

did not affect the incidence of stereotypies in these latter
groups (Tables 7-10).

Stereotypic Responses to the DA D2 Specific Agonist
LY 171555 in Rats Treated During Development
with LY 171555. with or without Neonatal 6-OHDA
When rats treated daily during postnatal development
with LY 171555 (3.0 mg/kg/d, i.p.) were challenged with an
acute dose of LY 171555 (3.0 mg/kg, i.p.) at 49 to 51 days
from birth, there was a marked increase in the score for
eating behavior (15.0 + 4.2 vs. 4.6 ±2.3) compared to that
for the diluent control (Figure 11 and Table 8).

Hats co

treated in development with LY 171555 and 6-OHDA had
increased scores for digging behavior (15.2 + 6 . 2 vs. 0.4+
0.2 for the control), in response to the challenge dose of
LY 171555 (3.0 mg/kg, i.p.) (Figure 9),

In the same group

(LY 171555 + 6-OHDA), the incidence of LY 171555-induced
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sniffing, licking, grooming, gnawing, eating, locomotion,
rearing, jumping, taffy pulling, paw treading, head nodding,
and self-biting was not different from the control group
(Tables 7-10).

Development of Striatal D1 Receptors in Postnatallv-Treated
Pats
Administration of the DA D1 receptor agonist or
antagonist to rats once a day for 32 successive days from
birth had no effect on striatal DA D1 receptor number and D1
receptor affinity at 8 weeks of age (Table 11).

In the

group of rats treated in development with SKF 38393 (3.0
mg/kg/d, i.p.), the in vitro binding of [3H3SCH 23390 to
striatal homogenates was not different from the control
group (Bmax = 6.6 + 2.2 fmol/mg tissue and Kd = 240.3 +53.3
pM vs. 1 9 . 1 + 6 . 8 and 416.8 + 101.5, respectively, for the
diluent control group).

Groups that were treated neonatally

with 6-OHDA (200 Mg, i.c.v., at 3 days of age) showed no
difference in binding parameters from control.

£n vitro

binding of [3H]SCH 23390 to striatal homogenates showed that
the Bmax was 17.8 + 5.6 fmol/mg tissue and the Kd was 600.0
+ 101.9 for the 6-OHDA group, vs.

1 9 . 1 + 6 . 8 and 416.8 +

101.5, respectively, for the diluent control group (Table
11).

Rats treated alone with 6-OHDA (200 /<g, i.c.v., at 3

days of age), in combination with SKF 38393 (3.0 mg/kg/d,
i.p., for 32 days), or SCH 23390 (0.3 mg/kg/d, i.p., for 32
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days) also were not statistically different from the control
group.

Development of Striatal P2 Receptors in Postnatally-Treated
Rats
When the DA D2 receptor agonist or antagonist was
administered to rats once a day for 32 successive days from
birth there was no effect on the development of striatal DA
D2 receptors at 8 weeks of age (Table 12).

In the group of

rats treated chronically with LY 171555 (3.0 mg/kg/d, i.p.)
the in vitro binding of [3H]spiroperidol to striatal
homogenates was not different from that of the control group
(Bmax = 14.2 ± 1,9 fmol/mg tissue and Kd = 57.5 ± 7.2 pM vs.
15.9 + 2.0 and 73.3 + 5.4, respectively).

Groups treated

neonatally with 6-OHDA (200 Ag, i.c.v., at 3 days of age)
showed no difference in binding parameters from the control.
In vitro binding of [3H]spiroperidol to striatal homogenates
showed that the Bmax was 20.0 + 2.1 fmol/mg tissue and the
Kd was 74.8 + 5.3

in the 6-OHDA group, vs. 15.9 + 2.0 and

73.3 ± 5.4, respectively, for the diluent control group
(Table 12).

In rats treated with 6-OHDA (200 /fg, i.c.v., at

3 days of age), alone or in combination with LY 171555 (3.0
mg/kg/d, i.p., for 32 days) or spiroperidol (0.3 mg/kg/d,
i.p., for 32 days), the binding parameters for D2 receptors
were not different from the control group.
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popamine_pl Receptor Equilibrium. Binding Studies
Dopamine D1 receptor equilibrium binding studies were
performed on striatal tissue taken from similar parts of the
striatum at 8 weeks.from birth.

Rats were treated

chronically with diluent, SKF 38393 (3.0 mg/kg/d, i.p,), or
SCH 23390 {0.3 mg/kg/d, i.p.) in combination with 6-OHDA
(200 yUg, i.c.v. at 3 days of age) or its diluent.

It was

found that these treatments did not alter the Bmax or the Kd
vs. the diluent control group (Table 11).

Dopamine D2 Receptor Equilibrium Binding Studies
Dopamine D2 receptor equilibrium binding studies were
performed on striatal tissue taken from similar parts of the
striatum at 8 weeks from birth.

Rats were treated

chronically with diluent, LY 171555 (3.0 mg/kg/d, i.p.), or
spiroperidol (0.3 mg/kg/d, i.p.) in combination with 6-OHDA
(200 /fg, i.c.v. at 3 days of age) or its diluent.

It was

found that these treatments did not alter the Bmax or the Kd
vs. the diluent control group (Table 12).
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Table 3
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
!DEVELOPMENT]kL
TREATMENT
SNIFFING
iVEHICLE +
| DILUENT
| SKF38393
I LY171555
! SCH23390
! SPIPERONE
|6-OHDA +
! DILUENT
! SKF38393
! LY171555
! SCH23390
! SPIPERONE

|
\
i

BEHAVIORAL SCORE

24.2
26.6
18.8
18.6
19.8

+ 4.3
+ 6.2
i- 2.0
+ 1.0
+ 5.3

LICKING

GROOMING

|
i

5.2 ± 2.1
8.6 + 2.6

3.4 + 1.6
5.6 + 1.7
7.6 + 3.1
6.0 + 1.6
3.6 + 1.6

|
J
|
|
|

9.6 ± 2.5
6.6 + 1.6
5.4 + 1.7

1
1
24.7
31.8
27.8
24.2
28.3

+
+
+
+
+

3.8
1,8
4.0
5.2
5.8

5.2 + 2.9
24.0 + 3.2i,',c'*
2.4 + 1.0
8.0 + 2.1
10.0 + 3.8

2.7 + 1 . 6
15.6 + 4.41’b'(
2.0 + 0.6
4.4 + 1.4
2.0 + 0.9

|
!
|
j
!
1
»

Rats were treated i.p., daily for the first 32 days from
birth, with diluent, SKF 38393 (3 mg/kg/d), LY 171555 (3
mg/kg/d), SCH 23390 (0.3 mg/kg/d) or spiroperidol
(spiperone) (0.3 mg/kg/d) in combination with i.c.v. 6-OHDA
(200 JXg, salt form, at 3 days of age) or its diluent.
Animals were challenged with SKF 38393 (3 mg/kg, i.p.) at
44-47 days from birth, and were observed, beginning 10 min
after the challenge dose. Numbers of episodes of each
stereotypic behavior were summed over 9 one min periods,
separated by a 10 min interval. Each min was subdivided
into 15 sec sessions, and a score of 1 was assigned if a rat
demonstrated a particular behavior during this interval.
The maximum score for each min was 4. For the 90 min
period, the maximum score was 36 for each behavior.
Results are expressed as the Mean ± S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent1 group that were
challenged with SKF 38393.
b, p < 0.05, compared to the corresponding control group.
c, e < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, e < 0.05, compared to the same treatment with different
challenge.
e, e < 0.05, compared to 'Vehicle + Diluent1 group that were
challenged with LY 171555.
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Table 4
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
DEVELOPMENT;\L
TREATMENT

BEHAVIORAL SCORE
DIGGING

VEHICLE +
DILUENT
SKF38393
LY171555
SCH23390
SPIPERONE

2.0 + 0.7

2.8 + 1.2
0.4 + 0.2
1.8 + 0.4
2.4 ± 0,7

GNAWING

8.0 +
15.8 +
8.0 +
11.0 +
6.2 +

0.8

11.3
11.2
6.0
8.4
12.3

2.2
4.1
2.4*
2.4
5.1

2.4
1.9
1.4
1,4*

EATING

1.0 + 0.8
2.6 + 1.1
1.0 ± 0.5
0.4 + 0.4
2.0 + 1.1

6-OHDA +
DILUENT
SKF38393
LY171555
SCH23390
SPIPERONE

2.5 + 1.6
13.4 + 4.9*
2.4 + 0.9
2,8 + 0.8
2.8 + 1.3

Legend as in Table 3

+
+
+
+
+

1.5 + 1.2
1.2 + 0.4
0.6 + 0.4
1.2 + 0.8
2.5 + 0.9
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Table 5
Behavioral Effects Induced by SKF 38393 (3.0 ms/kg, i.p.) in Rats
that Received Repeated Treatment with 01 and D2 Receptor Agonists
or Antagonists During Postnatal Development
DEVELOPMENT1L
TREATMENT

VEHICLE +
DILUENT
SKF38393
LY171555
SCH23390
SPIPERONE

BEHAVIORAL SCORE
JUMPING

LOCOMOTION

REARING

7.6
12.4
3.0
5.8
5.8

+
±
+
+
+

2.7
3.2
0.8
2.4
2.3

8.0
13.0
2.4
3.6
3.4

+
+
+
+
+

3.4
4.0
1.1
1.4
1.4

0.0
0.2
0.0
0.0
0.2

10.5
26.8
16.2
11.0
16.8

+
+
+
+
+

3.8
3.51

10.0
18.0
12.8
10.8
17.8

+
+
+
+
+

4.6
3.4
7.3
4.3
6.4

0.0 ± 0.0

±
+
+
+
±

0.0
0.2
0.0
0,0
0.2

6-OHDA +
DILUENT
SKF38393
LY171555
SCH2339D
SPIPERONE

6.1
4.5
3.6

Legend as in Table 3

8.0 + 4.6**l't'd't j
5.6 ± 3.7
0.2 + 0.2
0.3 + 0.3
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Table 6
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
|DEVELOPMENT.\L
ITREATMENT

BEHAVIORAL SCORE

TAFFY PULLING
!VEHICLE +
! DILUENT
| SKF38393
I LY171555
j SCH23390
i SPIPERONE
|6-OHDA +
! DILUENT
I SKF38393
! LY171555
j SCH23390
! SPIPERONE

1.4
3.6
2.8
1.8

1.8

±
+
+
+
+

0.9
1.3
1.4
0.5

1.1

PAH TREADING
2.2 + 1.3
2.0 + 1.1
0.0 + 0.0
0.8 ± 0.8
0.0 + 0.0

8.0
2.2 + 1.4
16.8 + 3.iatb.c,d,e 14.0 +
11.2
1.2 + 0.5
4.0 + 1.3
6.0
1.0 + 0.7
9.8

Legend as in Table 3

+ 3.6
3.31,e,e
+ 6.9
+ 2.6
+ 3.9

HEAD NODDING
3.6 ± 1.7

8.6 + 3.4
6.0 + 1.1
6.4 + 1.9
7.6 + 3.9

5.0 ±
2.6 4
5.4 4
9.8 4
5.3 4

2.6

0.8
3.9
3.5
2.1
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Figure 3. Behavioral Effects Induced by SKF 38393 (3 mg/kg,
i.p.) in Rats that Received Repeated Treatment with D1 or D2
Receptor Agonists During Postnatal Development. Rats were
treated i.p., daily for the first 32 days from birth, with
diluent, SKF 38393 (3 mg/kg/d), or LY 171555 (3 mg/kg/d) in
combination with i.c.v. 6-OHDA (200/Cg, salt form, at 3 days
of age) or its diluent. Animals were challenged with SKF
38393 (3 mg/kg, i.p.) at 44-47 days from birth, and were
observed, beginning 10 min after the challenge dose. Numbers
of episodes of each stereotypic behavior were summed over 9
one min periods, separated by a 10 min interval. Each min
was subdivided into 15 sec sessions, and a score of 1 was
assigned if a rat demonstrated a particular behavior during
this interval. The maximum score for each min was 4. For the
90 min period, the maximum score was 36 for each behavior.
Results are expressed as the Mean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent* group that were
challenged with SKF 38393.
b, jp < 0.05, compared to the corresponding control group.
c, d < 0.05, compared postnatal treatment with 6-OHDA vs.
witnout 6-OHDA.
d, p < 0.05, compared to the same treatment with different
challenge.
e, p < 0.05, compared to ’Vehicle + Diluent1 group that were
challenged with LY 171555.
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Table 7
Behavioral Effects Induced by LY 171555 (3.0 ms/kg, i.p.) in Rats
that Received Repeated Treatment vith D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
[DEVELOPMENT;\L
JTREATMENT

BEHAVIORAL SCORE
SNIFFING

[VEHICLE +
| DILUENT
{ SKF38393
[ LY171555
SCH23390
! SPIPERONE

!
[

31.0
32.2
32.6
30.8
29.4

+
+
+
+
±

1.7
0.9
1.3
1.2
1.5

1

LICKING

GROOMING

0.2 + 0.2
0.2 + 0.2

0.0 + 0.0

2.2 + 1.3
0.4 + 0.2
0.0 + 0.0

|
i
■
i
!
|
[
!

o.o + o.o
1.2 + 1.2
0.0 + 0.0
0.0 + 0.0
_________________ 1
r

!6-0HDA +
! DILUENT
| SKF38393
| LY171555
! SCH23390
| SPIPERONE

1
31.6
21.8
34,0
26.8
30.3

+
+
+
+
+

2.2
5.5
0.8
3.3
2.3

8.6 + 5.9
20.6
2.2
3.8
4.5

+
+
±
+

6.5,,',C|t
0.9
2.5
2.0

8.0 + 5.9

!

2o.o + 6.9*'b'e'e [
1.2 + 1.2
[
2.4 + 1.5
4.0 + 2.0
...

[
|

1
1

Rats were treated i.p., daily for the first 32 days from
birth, with diluent, SKF 38393 (3 mg/kg/d), LY 171555 (3
mg/kg/d), SCH 23390 (0.3 mg/kg/d), or spiroperidol
(spiperone) (0.3 mg/kg/d) in combination with i.c.v. 6-OHDA
(200 Mg, salt form, at 3 days of age) or its diluent.
Animals were challenged with LY 171555 (3 mg/kg, i.p.) at
49-51 days from birth, and were observed, beginning 10 min
after the challenge dose. Numbers of episodes of each
stereotypic behavior were summed over 9 one min periods,
separated by a 10 min interval. Each min was subdivided
into 15 sec sessions, and a score of 1 was assigned if a rat
demonstrated a particular behavior during this interval.
The maximum score for each min was 4. For the 90 min
period, the maximum score was 36 for each behavior.
Results are expressed as the Hean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent’ group that were
challenged with SKF 38393.
b, e < 0.05, compared to the corresponding control group.
c, e < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, e < 0.05, compared to the same treatment with different
challenge.
e, e < 0.05, compared to 'Vehicle + Diluent’ group that were
challenged with LY 171555.
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Table 8
Behavioral Effects Induced by LY 171555 (3.0 us/kg, i.p.) in Hats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
{DEVELOPMENT;4L
{TREATMENT

BEHAVIORAL SCORE
DIGGING

{VEHICLE +
{ DILUENT
{ SKF38393
{ LY171555
i SCH23390
{ SPIPERONE
,'6-OHDA +
{ DILUENT
! SKF38393
{ LY171555
{ SCH23390
{ SPIPERONE

{
{
i

GNAWING

+ 0.2
+ 2.4
+ 1.4
+ 2.6
+ 2.2

23.6
23.6
26.2
26.0
19.0

+
+
+
+
±

1.3
4.6
2.7*'d
3.5*
6.1

2.2 ± 1.0

19.4
4.4
16.2
27.0
23.0

+
+
+
+
+

2.3
1.5*
3.7
3.8*'d
5.8

0.4
6.2
4.6
5.6

2.2

20.0
15.2
4.4
8.0

+ 3.2l'i'tt*
+
+ 2.3
+ 4.5

Legend as in Table 7

EATING

{

1
1

4.6 + 2.3
{
9.4 + 4.5
{
15.0 + 4.2*'l'd't |
9.6 + 2.3
|
14.0 ± 4.9*,d
{
__________________ i
i
4.2 4
1.0 4
5.6 ±
10.4 ±
6.3 4

2.1

0.8
1.4
3.6
2.8

{
{
{
|
{
i
i
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Table 9
Behavioral Effects Induced by LY 171555 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
|DEVELOPMENT,\L
ITREATMENT

{VEHICLE +
j DILUENT
! SKF38393
! LY171555
! SCH23390
{ SPIPERONE

BEHAVIORAL SCORE

LOCOMOTION

REARING

JUMPING

15.2
18.6
17.6
15.6
10.2

0.4 ± 0.4
0.2 ± 0.2
0.0 + 0.0
0.2 + 0.2
0,6 + 0.6

±
+
+
+
+

2.8
4.0
3.9
2.9
3.2

0.4
3.8
2.6
0.4
4.4

16.0 +
8.8 +
23.8 +
14.0 +
13.8 +

4.3
2.9
4.4
4.2
2.3

4.8 + 3.8
7.0 + 2.7

±
+
+
+
+

0.2
2.6
1.9
0.2
2.2

J6-OHDA +
|
!
I
{
!

DILUENT
SKF38393
LY171555
SCH23390
SPIPERONE

Legend as in Table 7

5.6 + 4.2

0.0
0.0
0.2
1.0

2.0 + 1.2

0.3 ± 0.3

3.6 + 2.2

± 0.0
± 0.0
+ 0.2
± 1.0
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Table 10
Behavioral Effects Induced by LY 171555 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
[DEVELOPMENT;\L
[TREATMENT
TAFFY PULLING
[VEHICLE +
[ DILUENT
[ SKF38393
[ LY171555
[ SCH23390
[ SPIPERONE
[6-0HDA +
[ DILUENT
[ SKF38393
[ LY171555
[ SCH23390
[ SPIPERONE

[
[

BEHAVIORAL SCORE

0.0
0.0
0.0
0.0
0.0

+
±
+
+
+

0,0
0.0
0.0
0.0
0.0

0.0 + 0.0
0.4 + 0,4
0.0 + 0.0
0.0 + 0.0
0.0 + 0,0

Legend as in Table 7

PAW TREADING

0.0
0.0
0.0
0.0
0.0

+
+
+
±
+

0.0
0.0
0.0
0.0

1.6 + 1.0
4.6 + 2.4
0.2 + 0.2
0.4 + 0.2
0.0 + 0.0

HEAD NODDING

[

1.4 + 0.6
1.0 + 0.6
2.2 + 1.4
1.2 ± 0 . 5
0.6 + 0.2

[
[
[
[
[

0.8 + 0.8

[
[
[
[
[

0.4 + 0.2
2.2 + 2.2
0.4 ± 0.2
0.8 ± 0.8
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Figure 9. Behavioral Effects Induced by LY 171555 (3.0
mg/kg, i.p.) in Rats that Received Repeated Treatment with
D1 or 02 Receptor Agonists During Postnatal Development.
Rats were treated i.p,, daily for the first 32 days from
birth, with diluent, SKF 38393 (3 mg/kg/d), or LY 171555 (3
mg/kg/d) in combination with i.c.v. 6-OHDA (200/tg, salt
form, at 3 days of age) or its diluent. Animals were
challenged with LY 171555
(3 mg/kg, i.p.) at 49-51 daysfrom
birth, and were observed,
beginning 10 min after the
challenge dose. Numbers of episodes of each stereotypic
behavior were summed over
9 one min periods, separated bya
10 min interval. Each min was subdivided into 15 sec
sessions, and a score of 1 was assigned if a rat
demonstrated a particular behavior during this interval. The
maximum score for each min was 4. For the 90 min period, the
maximum score was 36 for each behavior.
Results are expressed as the Mean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent' group that were
challenged with SKF 38393.
b, j? < 0.05, compared to the corresponding control group.
c, j> < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, p < 0.05, compared to the same treatment with different
challenge,
e, p < 0.05, compared to 'Vehicle + Diluent* group that were
challenged with LY 171555.
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Table 11
Characteristics of Striatal D1 Receptors in Postnatally-Treated
Rats, as Determined by Ip Vitro Binding of [3HJSCH 23390

Treatment

Kd
(pM)

Binax
(fmol/ms tissue)

Vehicle +
Diluent

19.1 + 6.8

SKP38393

6.6 ± 2.2

240.3 ±

53.3

SCH23390

15.9 + 3.8

466.4 +

79.6

Diluent

17.8 ± 5.6

600.6 + 101.9

SKF38393

10.7 ± 2.6

439.4 ±

SCH23390

10.2 ± 2.3

508.8 + 103.2

416.8 ± 101.5

6-OHDA +

Each value is the Mean + S.E.M. of 5 tissues.

63.5
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Table 12
Characteristics of Striatal D2 Receptors in Postnatally-Treated
Rats, as Determined by Ip Vitro Binding of [3H]spiroperidol

Treatment

Kd
(pM)

Bmax
(fmol/mg tissue)

Vehicle +
Diluent

15.9 ± 2.0

73.3 + 5.4

LY171555

14.2 + 1.9

57.5 ± 7.2

Spiroperidol

26.0 + 2.3

96.0 + 8.1

Diluent

20.0 + 2.1

74.8 ±

LY171555

22.6 ± 4.9

104.7 + 16.5

Spiroperidol

27.6 + 4.1

100.7 ± 12.0

6-OHDA +
5.3

Each value is the Mean + S.E.M. of 5 tissues.

*

CHAPTER 4
Discussion

Enhanced Yawning and Eating Responses to the DA D2 Specific
Agonist LY 171555 in Rats Treated During
Development with LY 171555
Yawning behavior appeared to be a well-suited model to
study the function of the dopaminergic system.

It provided

a functional means for evaluating potential new dopamine
agonists.

Yawning has been associated with agonist

activation of DA D2 receptors (Nickolson and Berendsen,
1980; Yamada and Furukawa, 1980; Gower et al., 1984; Stahle
and Ungerstedt, 1984; Serra et at., 1983a,b; 1984b).

Low

doses of DA agonists have been reported to reduce
schizophrenic morbidity and symptoms of hyperkinetic
disorders (see references in Stahle and Ungerstedt, 1989).
In view of these clinical findings, it is important to
establish experimental models for effects of low doses of DA
agonists and to elucidate the underlying pharmacological
mechanisms.

Yawning is one of the candidate behaviors.

Yawning is also of clinical interest since it has been
reported that psychotics rarely yawn, and yawning is
symptomatic in a wide range of CHS disorders such as brain
lesions, tumors, hemorrhage, motion sickness, chorea, and
encephalitis (see references in Laping and Ramirez, 1988).
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Yawning is considered to be therapeutic in preventing post
operative respiratory complications and in adjusting the air
pressure in the middle ear (see references in Frovine et
al., 1987).
It is now well accepted that yawning involves DA D2
receptors, which have characteristics in common with the D2
autoreceptor (Gower et al.f 1984).

This hypothesis is

mainly based on the observation that the minute doses of DA
receptor agonists needed to produce yawning are within the
same range as those needed to stimulate DA autoreceptors.
Higher doses of DA agonists, which stimulate postsynaptic DA
receptors as well, produce locomotor hyperactivity and
stereotypy and suppress yawning.

The presynaptic origin of

the yawning response to DA agonists is further suggested by
the fact that this behavior is abolished by bilateral 6OHDA-induced denervation of the striatum (Dourish and
Cooper, 1985) and olfactory tubercles (Protais et al.,
1983), and by the fact that yawning is elicited by DA
agonists such as 3-(3-hydroxyphenyl)-N-n-propylpiperidine
(3PPP) (Gower et al., 1984; Stahle and Ungerstedt, 1984) and
TL-99 (Mogilnicka et al., 1984), which are considered to
preferentially or selectively stimulate DA autoreceptors.
On the basis of these observations it has been proposed by
various authors (Mogilnicka and Klimek, 1977; Nickolson and
Berendsen, 1980; Yamada and Furukawa, 1980; Gower et al.,
1984; Stahle and Ungerstedt, 1984; Serra et at., 1983a,b;

1984b) that yawning is a behavioral consequence of DA
autoreceptor-mediated inhibition of DA transmission.

This

hypothesis, however, has been challenged by the fact that
yawning appears about 9 days postnatally, before maturation
of presynaptic dopamine receptors (Arnt, 1987), and by the
fact that DA agonist-induced yawning is not due to a
decrease in the extracellular levels of DA (Stahle and
Ungerstedt, 1989).

DA agonists can induce yawning when DA

neurotransmission is apparently enhanced (Stahle and
Untgerstedt, 1989),
It has recently been proposed that DA agonists induce
yawning by actions outside the striatum, namely by releasing
oxytocin in the CNS, possibly in the paraventricular nucleus
(PVN) of the hypothalamus.

This nucleus contains the cell

bodies of DA neurons of the A14 group which constitute the
so-called incerto-hypothalamic

DA system together withthose

of the All and A13 groups.

D2 receptors have been

DA

identified in these regions (Argiolas et al., 1987; Melis et
al., 1986; 1987).
Results of this study revealed that rats treated during
postnatal development with the

DA D2 agonist LY 171555

exhibited a marked increase in

LY 171555-induced yawning at

5 to 6 weeks after birth.

This enhanced behavioral response

was not accompanied by an increased binding of
[3H]spiroperidol to DA D2 receptors at 55-57 days from
birth.

It was not clear whether these results indicated
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that [3H]spiroperidol binds to a site (striatum) which did
not represent the action of LY 171555 or whether other
mechanisms (supersensitivity) were responsible for the
enhanced responses of this DA D2 agonist in the LY 171555
group of rats.
The yawning rate in the control group corresponded to
that at the reported peak of the LY 171555 dose-response
curve (Serra et al., 1987), while the yawning response rate
in the LY 171555 group was greater than in any previous
report, to the researchers knowledge, suggesting that the
enhanced response was not a shift in the dose-response
curve.

These results suggested that LY 171555 treatment in

development produced a supersensitive animal model for
yawning behavior.
Yawning has been suggested as a behavior subserving
arousal when attention is decreasing in front of a danger.
Yawning might then indicate a low degree of arousal mediated
by the activation of the most sensitive population of DA
receptors.

Further activation of DA transmission might

progress to full arousal, exploratory behavior, and then to
stereotyped sniffing, licking, and gnawing.

This hypothesis

offers a logical explanation for the fact that yawning and
stereotypy are mutually exclusive.

Namely, when the latter

is elicited, the former is suppressed (Protais et al.,
1983).

Here it was proposed that the DA D2 agonist LY

171555 produced yawning by stimulating DA D2 receptors in

the PVN of the hypothalamus which may represent the most
sensitive group of D2 receptors*

Greater stimulation by the

agonist or increased sensitivity in the striatal DA
receptors may lead to stimulation of the DA receptors in the
striatum or activation of these receptors even with the same
degree of the stimulus, respectively.

Neonatal 6-0HDA-

lesioned rats demonstrate a supersensitivity to DA D1
agonists (Breese et al., 1984; 1985a,b; 1986).

Furthermore,

supersensitivity can be primed (increased) by repeated
administration of specific DA D1 agonist SKF 38393,

Those

observations seem to be in accord with the low number of
yawns that was observed in the group treated with 6-OHDA
plus SKF 38393.
Dopaminergic mechanisms may be involved in the
regulation of feeding behavior.

Electrical stimulation of

the lateral hypothalamus can elicit feeding in food-satiated
animals.

This stimulation-induced feeding is disrupted by

neuroleptic treatment (Streather and Bozarth, 1987).
Selective DA D2 receptor antagonists decrease the sham
intake of sucrose in food-deprived rats (Schneider et al.,
1986),

DA D2 receptor-selective agonists increase

consumption of food pellets in rats (solid diets) which are
blocked by D2 antagonists or by D1 antagonists, while a D1
receptor selective agonist SKF 38393 decreases intake and
produces anorexia (Martin-Iversen and Dourish, 1988).
Yawning, as mentioned, is considered a behavior
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subserving arousal when attention is decreasing in front of
a danger, so it might be considered to indicate a low degree
of arousal, mediated by the activation of the most sensitive
population of DA receptors.

On the other hand, stress- or

stimulation-induced eating could reflect a general "arousal"
effect with specific behaviors determined by salient
environmental stimuli (Martin-Iversen and Dourish, 1988).
Results of this study showed that rats treated during
postnatal development with a DA D2 agonist LY 171555
exhibited a marked increase in LY 171555-induced eating at 7
weeks after birth.

This enhanced behavioral response was

not accompanied by an increased binding of [3H]spiroperidol
to DA D2 receptors at 7-8 weeks from birth.

It was not

clear if these results were suggesting that [3H]spiroperidol
is binding to a site (striatum) which did not represent the
action of LY 171555 to elicit eating or whether other
mechanisms (supersensitivity) were responsible for the
enhanced responses of this DA D2 agonist in LY 171555
treated rats.
In conclusion, because of the fact that both yawning
and eating behaviors were enhanced in the group that was
treated during the postnatal period with a specific DA D2
agonist LY 171555 and because these behaviors reflected a
degree of "arousal," it was suggested that D2 agonist
treatment during development produced a supersensitivity or
a change in number of DA D2 receptors which mediated these
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behaviors.

Further studies are needed to determine the

relationship between these behaviors and the numbers of DA
D2 receptors in the hypothalamus and to determine the
possible usefulness of D2 agonist-treated rats as models to
study mechanisms associated with eating behavior.

Enhanced Perioral Response to the DA D2 Specific Antagonist
Spiroperidol in Neonatal 6-OHDA-Lesioned Rats
Oral dyskinesia represent an excess number of
involuntary perioral movements.

This behavior appears with

increasing frequency during continued stable therapy in
Parkinsonian patients, perhaps reflecting increasing
denervation supersensitivity of DA receptors (Marsden,
1982}.

Oral dyskinesia, the most outstanding characteristic

of tardive dyskinesia (TD), is observed in rats treated
chronically with several neuroleptics (Clow et al., 1979a,b;
Waddington and Gamble, 1980; Waddington et al., 1981).
These movements are most pronounced when DA D1 receptors are
stimulated or when DA D2 receptors are inhibited (Holloy et
al., 1986; Rosengarten et al., 1986; Koshikawa et al., 1987;
Molloy and Waddington, 1988) or reduced in number following
prenatal drug intervention, strain difference, or in
senescence (Rosengarten et al., 1983c; 1986).

When DA D2 as

well as DA D1 receptors are stimulated, these movements are
least prominent (Rosengarten et al., 1986; Johansson et al.,
1987), an observation that may prove relevant to the
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treatment of TD and Tourette's syndrome.

These movements

can be suppressed by the selective DA D1 antagonist SCH
23390 or the cholecystokinin octapeptide (Stoessl et al.,
1989).

The molecular and/or neural mechanism(s) involved in

the receptor modulation in TD are unknown.
An important finding in the present study was that
perioral movements could be produced in neonatal 6-OHDAtreated rats in high frequency when a very low dose of the
DA D2 antagonist spiroperidol was administered.

This animal

model might be of importance for studying mechanisms
involved in the mediation of oral dyskinesia in humans.
The availability of this neurochemical model with
increased susceptibility for perioral movements may permit
screening of a variety of pharmacological agents that could
minimize the TD syndrome observed after long-term
neuroleptic administration.

The demonstration that neonatal

6-OHDA-treated rats have D1 dominance (supersensitivity)
without alteration in the number of binding sites

vitro

for [3H]SCH 23390 and [3H]spiroperidol to striatal
homogenates is compatible with the findings of Breese and
co-workers (1984, 1985a, 1986, 1987; Duncan et al., 1987).
The findings in this study suggested that the mechanisms
involved in this disorder were at a site beyond the receptor
complex.

It has been suggested that clinical

psychopathological disorders in humans, such as
schizophrenia and TD, represent conditions in which the
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defect is a developmental or drug-induced permanently
altered state.

With the ability of neonatal 6-OHDA-lesions

to produce permanent effects on the dopaminergic system, it
can be seen that the present behavioral model might more
closely reflect the clinical situation.

Future

investigations in the neonatal 6-OHDA-treated rats will test
the usefulness of this proposed model.

Enhanced Stereotypic Response to the DA D1 or D2 Specific
Agonists SKF 38393 or LY 171555 in Rats Treated
During Development with both SKF 38393 and 6-OHDA
The study of animal behaviors induced by centrallyacting dopaminergic agents is a classical means of
investigating the pharmacology of the DA system and the
pathophysiology of human neuropsychiatric diseases.

So it

was sought first to characterize the behavioral consequences
of independent D1 receptor stimulation in rats with an
intact dopaminergic system and other rats with a 6-OHDA
lesioned-system.
Following neonatal, but not adult 6-OHDA lesions, rats
exhibit greater behavioral supersensitivity to a DA D1
agonists than to DA D2 agonists (Breese et al., 1985a,b,
1986).

The sensitivity of DA D1 receptors increases with

repeated exposure to a DA agonist in the neonatally 6-OHDAtreated rats (priming).

Supersensitivity to DA agonists

develops during the first days after denervation and reaches

a steady state depending on the number of treatments, the
dose of drug used and the time after lesion.

The priming is

effective as a facilitatory factor for the expression of DA
receptor supersensitivity and provides a mechanism for the
strong enhancement of the effectiveness of the agonist or
for making otherwise ineffective doses of agonist effective
in producing an effect.

The changes induced by the primer

do not involve the DA receptor per se, and stimulation of DA
receptors could trigger some changes in neurons located
downstream from the DA receptor itself (Morelli et al.,
1989).

This priming phenomenon has not been associated with

DA D2 agonists (Breese et al., 1985b) and can be prevented
by the D1 antagonist SCH 23390 (Criswell et al., 1989).

The

priming phenomenon, which appears to be permanent (Criswell
et al,, 1989), suggests that DA D1 receptors may possess a
degree of plasticity that could have important implications
for understanding long-term changes in behavior associated
with repeated drug use or the basis of symptoms of childhood
disorders secondary to a central DA deficiency.
In this study priming of DA D1 receptor response was
reflected by an increase in the frequency of several
behaviors elicited by a challenge dose of the DA D1 agonist
SKF 38390 including licking, grooming, locomotion, jumping,
taffy pulling, and paw treading.

Priming of DA D1 receptor

responses was reflected by the increase in frequency of
several behaviors elicited by a challenge dose of the DA D2

agonist LY 171555 including licking, grooming, and digging.
While priming of the DA D2 receptor response has not been
observed with repeated administration of the DA D2 agonist
at weekly intervals (Criswell et al., 1989), this treatment
results in priming of responses to the DA D1 agonist in
neonatal 6-OHDA-lesioned rats (Criswell et al., 1989).
Present results show that priming of the DA D2 receptor
response is present and is reflected by an increase in the
frequency of digging behavior elicited by a challenge dose
of the DA D2 agonist LY 171555.

At present, it is not known

whether the time between treatments, the dose, and/or the
length of the treatment are/is an important determinant of
DA D2 receptor priming.
Although functional responses to SKF 38393 or LY 171555
are enhanced in rats treated developmentally with SKF 38393
or LY 171555 plus neonatal 6-OHDA, respective binding of
[3H]SCH 23390 or [3H]spiroperidol to striatal membranes from
these rats is not altered.
The absence of an association between the enhancement
of DA agonist-induced behavior and DA antagonist binding
suggests that there are deficiencies in the present
understanding of DA receptor mechanisms.

Change(s) in the

second or third messengers linked to these receptors or
change(s) in systems modulating DA-mediated effects may
explain this.

It is evident, however, that if any prolonged

treatment produces no change in the number of a receptor
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population, it cannot necessarily be concluded that there is
no effect on the kinetics of the processes determining
steady-state receptor levels (Norman et al., 1987).

Future

studies might investigate a molecular mechanism for the
enhanced behavioral responses observed in the absence of
changes in receptor number.
DA D1 receptors may play a role in the transition from
levels of arousal associated with behavioral efficiency to
states of hyperarousal associated with behavioral
disorganization.

At low levels of DA D1 receptor

stimulation (i.e., that produced by endogenous DA), DA D2
receptor activation elicits complex motor responses such as
locomotion and exploratory activity which are part of the
animal's endogenous behavioral repertoire.

This is seen,

for example, when normal animals are placed in a novel
environment.

These behaviors are purposeful, goal-oriented,

and associated with efficient motor responsiveness to a
variety of sensory stimuli (Braun et al., 1986).

In

contrast, higher levels of DA D1 receptor stimulation are
associated with diminished responsiveness to environmental
stimuli and in the appearance of stereotypic behaviors which
represent fragmentation and purposeless repetition of
elements of these same behaviors (Braun et al., 1986).
Acute mania, attention deficit disorders with hyperactivity
in children, Lesch-Nyhan disease, Gilles de la Tourette
syndrome, and certain types of schizophrenia have been

characterized as states of hyperarousal associated with
attention deficits and behavioral disorganization.

Priming

of the DA D1 receptor responsiveness in the neonatal 6-OHDAlesioned rat represents a model of a long-term change in
neural function associated with repeated activation of a
chemically defined receptor system.

As such, the underlying

neurochemical mechanisms that lead to this increased
sensitivity may be representative of changes in other
central processes requiring a "permanent" neural message
(Criswell et al,, 1989).

CHAPTER 5
Summary

The present investigation demonstrated the following:
1. The DA D2 agonist LY 171555, when given
chronically to rats in the postnatal period,
produced supersensitive behavioral responses,
namely yawning and eating, when these rats were
challenged as adults with the same D2 agonist.
2. [3H]SCH 23390 and [3H]spiroperidol binding to
striatal tissue was not altered in rats treated in
development with specific agonists or antagonists
for the D1 and D2 receptors.

A neonatal 6-OHDA

lesion did not modify binding in any of the
agonist- or antagonist-treated groups.
3. Neonatal 6-OHDA-lesioned rats may serve as a
useful animal model of tardive dyskinesia.
4. The ability of DA D2 receptors to be primed, as
demonstrated for the first time in this study, may
provide a means for studying particular
stereotypic behaviors in animals.
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